百日咳外膜囊泡疫苗的研究进展  

A review on pertussis outer membrane vesicle-based vaccines

作　　者：王丽婵(综述) 马霄(审校)[1] WANG Lichan;MA Xiao(National Institutes for Food and Drug Control,State Key Laboratory of Drug Regulatory Science,NHC Key Laboratory of Quality and Standardization of Biotech Products,NMPA Key Laboratory for Quality Research and Evaluation of Biological Products,Beijing 102629,China)

机构地区：[1]中国食品药品检定研究院、药品监管科学全国重点实验室、国家卫生健康委生物技术产品检定方法及其标准化重点实验室、国家药品监督管理局生物制品质量研究与评价重点实验室,北京102629

出　　处：《微生物学免疫学进展》2024年第5期65-70,共6页Progress In Microbiology and Immunology

基　　金：北京市自然科学基金海淀原始创新联合基金项目(L222010)。

摘　　要：虽然百日咳疫苗接种率很高,但百日咳发病率并未达到理想的控制水平,百日咳疫情在各个国家均有不同程度的反弹甚至暴发,说明当前所用的百日咳疫苗并不理想。为此,新一代百日咳疫苗的研究势在必行。目前已有多条途径开展新型百日咳疫苗的研发,现主要对百日咳外膜囊泡疫苗的研究作一概述。Although the pertussis vaccine vaccination rate is high,the incidence of pertussis has not reached desired lever of control.The pertussis epidemic rebounded or even broken out in many countries to different degree.This phenomenon indicates that the current pertussis vaccines are not ideal.For this reason,a new generation of pertussis vaccine research is imperative and there are many ways to develop it.In this review,we will focus on the development of pertussis outer membrane vesicle-based vaccines.

关 键 词：百日咳 疫苗 外膜囊泡 免疫 

分 类 号：R392[医药卫生—免疫学]